Third Kind Venture Capital
555 W. 18th StreetNew York, NY 10011-2822
Firm Size
- Assets Under Management (AUM):$783 Million
- Number of Funds:7
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Description
Third Kind Venture Capital is a venture capital firm based in New York, New York. The company focuses on investing in early-stage companies in the technology sector, with a particular emphasis on startups that are leveraging cutting-edge technologies such as artificial intelligence, blockchain, and virtual reality. Third Kind Venture Capital aims to support entrepreneurs who are shaping the future by providing them with capital, mentorship, and networking opportunities. The firm takes a hands-on approach to investing, working closely with its portfolio companies to help them accelerate their growth and achieve their strategic objectives. By leveraging its extensive network of industry experts and experienced entrepreneurs, Third Kind Venture Capital aims to be a trusted and valuable partner for its portfolio companies as they navigate the competitive and dynamic landscape of the technology industry.Latest News
Powered by
Jun 05, 2024: Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic Pipeline and Expand Depth and Breadth of Commercial Offerings
Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY). Bristol Myers Squibb previously entered into an oncology research collaboration with Envisagenics in 2022.